U
ALBO

UBS’s Albireo Pharma Inc ALBO Stock Holding History

UBS’s Portfolio ALBO Stock Details ALBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-33
Closed -$3K – 10874
2013
Q3 		$3K Buy
+33
New +$4.3K ﹤0.01% 9804

Other funds holding ALBO

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FNYS
First New York Securities New York $53.7M AUM 57.01% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SKK
Shepherd Kaplan Krochuk Boston, Massachusetts $119M AUM 8.32% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS's ALBO Position: Q3 2014 in Review

UBS increased its Albireo Pharma Inc (ALBO) stake by 79% in Q3 2014, buying an estimated $12K and bringing the position to 473 shares worth $23K. The position accounts for ﹤0.01% of the portfolio, ranked #7837.

UBS first reported a position in ALBO in Q2 2013 and has held it in 6 quarters since. The position peaked at $28K in Q4 2013. 41 funds tracked by Wall St. Rank hold ALBO as of Q3 2014.

  • UBS held 473 shares of Albireo Pharma Inc worth $23K as of Q3 2014.
  • UBS bought 209 Albireo Pharma Inc shares in Q3 2014, an estimated $12K.
  • Albireo Pharma Inc made up ﹤0.01% of UBS's portfolio in Q3 2014, its #7837 holding.
  • UBS first reported a position in Albireo Pharma Inc in Q2 2013 and has held it in 6 quarters since.
  • UBS's Albireo Pharma Inc position peaked at $28K in Q4 2013.
  • 41 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.